Evidence map›Paper›PMID 41729921›Full record

ArticlePloS one2026

Robust predictors for drug response of patients with acute myeloid leukemia.

Bahar Tercan

Abstract read
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Bahar TercanInstitute for Systems Biology, Seattle, Washington, United States of America.ORCID https://orcid.org/0000-0002-5332-264X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The significant heterogeneity in treatment responses among patients with acute myeloid leukemia (AML) underscores the critical need for accurate drug response prediction. We developed k-Top Scoring Pairs (kTSP) classifiers, ensemble methods that aggregate the relative expression of gene pairs. We compared their accuracy with that of state-of-the-art machine learning methods, linear and radial basis function support vector machines, random forest and elastic net regression classifiers for drug response prediction of patients with AML. Our results demonstrate that kTSP particularly outperforms other methods when the number of sensitive and resistant patients is imbalanced, a common challenge in clinical studies. Our approach is inherently robust to batch effects and uniquely suited for single-patient classification due to its rank-based methodology.

Indexed as

Antineoplastic AgentsLeukemia, Myeloid, AcuteClassification AlgorithmsHumansMachine LearningPrediction AlgorithmsPredictive Learning ModelsRandom ForestSupport Vector MachineAntineoplastic Agents

Identifiers

PMID41729921
PMCPMC12928390

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.